Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (OTC Pink - Current Information:NONOF)

Delayed Data
As of Jun 29
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
10:29am / Zacks.com - Paid Partner Content
What Is It About Novo Nordisk's Diabetes Drug That Makes It a Top Seller?
Jun 20 / MotleyFool.com - Paid Partner Content
Is $2.8 Billion Just The Beginning For This Novo Nordisk Diabetes Drug
9:24am / MotleyFool.com - Paid Partner Content
5 Companies We'd Buy and Hold for the Next 20 Years
Jun 20 / MotleyFool.com - Paid Partner Content
High Yield, Strong Returns: Sturm Ruger, Nu Skin Enterprises
Jun 23 / GuruFocus News - Paid Partner Content
Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease
Jun 18 / MotleyFool.com - Paid Partner Content
How Big Is the Diabetes Treatment Market?
Jun 22 / MotleyFool.com - Paid Partner Content
Getting OLD but want to be SLIM? There are ETFs for that
Jun 09 / CNNMoney.com

Today’s Trading

Previous close51.25
Today’s openn.a.
Day’s range-- - --
Average volume (3 months)40,022
Market cap$103.1B
Dividend yield1.90%
Data as of 06/29/2016

Growth & Valuation

Earnings growth (last year)+12.17%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)+1.54%
P/E ratio--


No competitors data available.


Next reporting date--
EPS forecast (this quarter)--
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%


Health Technology
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region


Chart unavailable

Partner Offers

Search for Jobs